Advertisement
Advertisement
RLMD
Relmada Therapeutics, Inc. Common Stock
3.90
USDSponsored
+0.13
+3.45%
Nov 06, 15:59 UTC -5
Closed
After-Market
3.90
0.00
+0.13%
Relmada Therapeutics, Inc. Common Stock (RLMD) Earnings
RLMD Earnings Reports
Positive Surprise Ratio
RLMD beat 11 of 25 last estimates.
44%
Next Report
In 3 Days
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.14
Implied change from Q2 26 (Revenue/ EPS)
--
/+27.27%
Implied change from Q3 25 (Revenue/ EPS)
--
/-53.33%
Relmada Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, RLMD reported earnings of -0.11 USD per share (EPS) for Q2 26, beating the estimate of -0.20 USD, resulting in a 45.95% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.01% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an increase of 27.27% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Relmada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Relmada Therapeutics, Inc. Common Stock reported EPS of -$0.11, beating estimates by 45.95%, and revenue of $0.00, 0% as expectations.
How did the market react to Relmada Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -8.01%, changed from $5.37 before the earnings release to $4.94 the day after.
When is Relmada Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Relmada Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Relmada Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.